Journey Medical Corp (DERM) Stock AnalysisDERMJourney Medical Corp

Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Journey Medical Corp (DERM) is a good buy right now due to its recent strong earnings report showing a 23% year-over-year revenue increase to $18.5 million in Q2 2026, alongside a significant reduction in net loss to $300,000. The current price of $7.47 is well below the analyst price target of $15, suggesting substantial upside potential. However, the forward P/E ratio of 212.77 indicates high valuation expectations, which is a risk to consider.

8 analysts cover DERM: 7 rate it Buy, 0 Hold and 1 Sell. The average price target is 14.00.